Weight Loss Data From Obese Mice Looks Promising For Alaunos Therapeutics, But Shares Drop

Alaunos Therapeutics Inc. (NASDAQ:TCRT) shares are down on Monday after the company announced preclinical proof-of-concept data for its lead drug candidate, ALN1003. Data ResultsThe latest findings from Alaunos indicate that ALN1003 has shown promising results in diet-induced obesity mouse studies, with treated mice experiencing a mean percent change in body weight loss of up to -12.9%.Peak reductions in absolute weight loss were observed by Day 13 and remained lower than DIO controls through Day 48.In the ...